Showing 931-940 of 1635 results for "".
- Harrow Health Changes Corporate Name to Harrow Inc.https://modernod.com/news/harrow-health-changes-corporate-name-to-harrow-inc/2481858/Harrow announced that effective today, it has changed its corporate name from “Harrow Health Inc.” to “Harrow Inc.” to align with the company’s current 5-year strategic plan, which includes an exclusive focus on eye care pharmaceuticals. “Gi
- Ciliatech Presents Preliminary 1-Year Study Results on Treating Open and Narrow Angle Glaucoma with CIDhttps://modernod.com/news/ciliatech-presents-preliminary-1-year-study-results-on-treating-open-and-narrow-angle-glaucoma-with-cid/2481814/Ciliatech announced it will present at the Ophthalmology Futures Symposium the preliminary results of a 1-year study of its clinical trial, SAFARI III, involving both open and narrow angle glaucoma patients. Preliminary outcomes show an excellent performance and safety profile, wit
- Bonnie Henderson, MD, Named Interim President and CEO of HelpMeSeehttps://modernod.com/news/bonnie-henderson-md-named-interim-president-and-ceo-of-helpmesee/2481776/Bonnie Henderson, MD, has been named interim president and CEO of global nonprofit HelpMeSee. HelpMeSee provides cataract treatment training using its simulation-based training system with the aim of increasing access to treatment and eradicating cataract blindness. &nbs
- Glauconix Changes Name to Humonixhttps://modernod.com/news/glauconix-changes-name-to-humonix/2481751/Glauconix Biosciences has changed its name to Humonix Biosciences as the company has expanded beyond glaucoma to technology can support various cell types. "What began as a specialization in glaucoma therapeutics has become a launchpad for developing new fibrotic and vascular
- Opthea Announces “Sozinibercept” as the Nonproprietary Drug Name for OPT-302https://modernod.com/news/opthea-announces-sozinibercept-as-the-nonproprietary-drug-name-for-opt-302/2481747/Opthea announced that the American Medical Association’s United States Adopted Names (USAN) Council has approved the nonproprietary drug name “sozinibercept” for the company’s lead biologic drug candidate, OPT-302. Sozinibercept (OPT-302) is
- Lars Ederleh Named New CSO at Schwind Eye-Tech-Solutionshttps://modernod.com/news/lars-ederleh-named-new-cso-at-schwind-eye-tech-solutions/2481731/Schwind eye-tech-solutions has named Lars Ederleh as Chief Sales Officer (CSO), effective this month. Bringing more than 20 years of international experience in laser technology, Mr. Ederleh will be in charge of the company’s sales and marketing operations.
- National Eye Institute Names Kapil Bharti New Scientific Directorhttps://modernod.com/news/kapil-bharti-is-neis-new-scientific-director/2481726/The National Eye Institute (NEI) has named Kapil Bharti was Scientific Director, effective May 2023. “Dr. Bharti is a world-class translational vision scientist, a thoughtful planner who understands interdisciplinar
- Nacuity Pharmaceuticals Advances Phase 1/2 Trial Evaluating NPI-002 Intravitreal Implant for the Delay of Cataract Progressionhttps://modernod.com/news/nacuity-pharmaceuticals-advances-phase-12-trial-evaluating-npi-002-intravitreal-implant-for-the-delay-of-cataract-progression/2481719/Nacuity Pharmaceuticals announced that a clinical trial site has been added to its phase 1/2 clinical trial evaluating NPI-002, a proprietary antioxidant molecule delivered via a sustained release intravitreal implant, for the delay of cataract progression in patients undergoing vitrectomy.
- SriniVas R. Sadda, MD, Named 2023-2024 ARVO President Electhttps://modernod.com/news/srinivas-r-sadda-md-named-2023-2024-arvo-president-elect/2481697/Doheny Eye Institute announced that SriniVas R. Sadda, MD, was named President Elect of the Association for Research in Vision and Ophthalmology (ARVO) during its 2023 annual meeting in New Orleans. Dr. Sadda has been a member of ARVO for a number of years, and s
- Reduction of Eyedrop Volume for Topical Ophthalmic Medications with the Nanodropper Bottle Adaptorhttps://modernod.com/news/reduction-of-eyedrop-volume-for-topical-ophthalmic-medications-with-the-nanodropper-bottle-adaptor/2481663/Nanodropper announced positive results from a research study conducted in collaboration with Leonard Seibold, MD, Professor of Ophthalmology at University of Colorado School of Medicine, which quantified eyedrop volume reduction and bottle life extension with the Nanodropper adaptor compared